126 related articles for article (PubMed ID: 38381399)
1. Relationship between serum β-hydroxybutyrate and hepatic fatty acid oxidation in individuals with obesity and NAFLD.
Moore MP; Shryack G; Alessi I; Wieschhaus N; Meers GM; Johnson SA; Wheeler AA; Ibdah JA; Parks EJ; Rector RS
Am J Physiol Endocrinol Metab; 2024 Apr; 326(4):E493-E502. PubMed ID: 38381399
[TBL] [Abstract][Full Text] [Related]
2. Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD.
Moore MP; Cunningham RP; Meers GM; Johnson SA; Wheeler AA; Ganga RR; Spencer NM; Pitt JB; Diaz-Arias A; Swi AIA; Hammoud GM; Ibdah JA; Parks EJ; Rector RS
Hepatology; 2022 Nov; 76(5):1452-1465. PubMed ID: 35000203
[TBL] [Abstract][Full Text] [Related]
3. Hepatic ketogenesis regulates lipid homeostasis via ACSL1-mediated fatty acid partitioning.
Ramakrishnan S; Mooli RGR; Han Y; Fiorenza E; Kumar S; Bello F; Nallanagulagari A; Karra S; Teng L; Jurczak M
Res Sq; 2023 Jul; ():. PubMed ID: 37503004
[TBL] [Abstract][Full Text] [Related]
4. β-Hydroxybutyrate is reduced in humans with obesity-related NAFLD and displays a dose-dependent effect on skeletal muscle mitochondrial respiration in vitro.
Mey JT; Erickson ML; Axelrod CL; King WT; Flask CA; McCullough AJ; Kirwan JP
Am J Physiol Endocrinol Metab; 2020 Jul; 319(1):E187-E195. PubMed ID: 32396388
[TBL] [Abstract][Full Text] [Related]
5. Emerging Role of Hepatic Ketogenesis in Fatty Liver Disease.
Mooli RGR; Ramakrishnan SK
Front Physiol; 2022; 13():946474. PubMed ID: 35860662
[TBL] [Abstract][Full Text] [Related]
6. Role of ketone signaling in the hepatic response to fasting.
Geisler CE; Ghimire S; Bogan RL; Renquist BJ
Am J Physiol Gastrointest Liver Physiol; 2019 May; 316(5):G623-G631. PubMed ID: 30767679
[TBL] [Abstract][Full Text] [Related]
7. Hmgcs2-mediated ketogenesis modulates high-fat diet-induced hepatosteatosis.
Asif S; Kim RY; Fatica T; Sim J; Zhao X; Oh Y; Denoncourt A; Cheung AC; Downey M; Mulvihill EE; Kim KH
Mol Metab; 2022 Jul; 61():101494. PubMed ID: 35421611
[TBL] [Abstract][Full Text] [Related]
8. Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.
Johnson K; Leary PJ; Govaere O; Barter MJ; Charlton SH; Cockell SJ; Tiniakos D; Zatorska M; Bedossa P; Brosnan MJ; Cobbold JF; Ekstedt M; Aithal GP; Clément K; Schattenberg JM; Boursier J; Ratziu V; Bugianesi E; Anstee QM; Daly AK; ;
JHEP Rep; 2022 Feb; 4(2):100409. PubMed ID: 35072021
[TBL] [Abstract][Full Text] [Related]
9. Whole-body substrate metabolism is associated with disease severity in patients with non-alcoholic fatty liver disease.
Croci I; Byrne NM; Choquette S; Hills AP; Chachay VS; Clouston AD; O'Moore-Sullivan TM; Macdonald GA; Prins JB; Hickman IJ
Gut; 2013 Nov; 62(11):1625-33. PubMed ID: 23077135
[TBL] [Abstract][Full Text] [Related]
10. Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease.
Daher S; Lev Cohen N; Massarwa M; Mahamid M; Nasser M; Hazou W; Oren R; Safadi R; Khoury T
PLoS One; 2018; 13(11):e0207479. PubMed ID: 30500848
[TBL] [Abstract][Full Text] [Related]
11. Dietary fatty acid oxidation is decreased in non-alcoholic fatty liver disease: A palmitate breath test study.
Naguib G; Morris N; Yang S; Fryzek N; Haynes-Williams V; Huang WA; Norman-Wheeler J; Rotman Y
Liver Int; 2020 Mar; 40(3):590-597. PubMed ID: 31762148
[TBL] [Abstract][Full Text] [Related]
12. TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation.
Park HS; Song JW; Park JH; Lim BK; Moon OS; Son HY; Lee JH; Gao B; Won YS; Kwon HJ
Autophagy; 2021 Sep; 17(9):2549-2564. PubMed ID: 33190588
[TBL] [Abstract][Full Text] [Related]
13. Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity.
Di Mauro S; Scamporrino A; Petta S; Urbano F; Filippello A; Ragusa M; Di Martino MT; Scionti F; Grimaudo S; Pipitone RM; Privitera G; Di Pino A; Scicali R; Valenti L; Dongiovanni P; Fracanzani A; Rabuazzo AM; Craxì A; Purrello M; Purrello F; Piro S
Liver Int; 2019 Sep; 39(9):1742-1754. PubMed ID: 31169972
[TBL] [Abstract][Full Text] [Related]
14. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
[No Abstract] [Full Text] [Related]
15. Higher hepatic advanced glycation end products and liver damage markers are associated with nonalcoholic steatohepatitis.
Priken K; Tapia G; Cadagan C; Quezada N; Torres J; D'Espessailles A; Pettinelli P
Nutr Res; 2022 Aug; 104():71-81. PubMed ID: 35635899
[TBL] [Abstract][Full Text] [Related]
16. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
[TBL] [Abstract][Full Text] [Related]
17. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
18. Branched chain amino acids and carbohydrate restriction exacerbate ketogenesis and hepatic mitochondrial oxidative dysfunction during NAFLD.
Muyyarikkandy MS; McLeod M; Maguire M; Mahar R; Kattapuram N; Zhang C; Surugihalli C; Muralidaran V; Vavilikolanu K; Mathews CE; Merritt ME; Sunny NE
FASEB J; 2020 Nov; 34(11):14832-14849. PubMed ID: 32918763
[TBL] [Abstract][Full Text] [Related]
19. Hepatic ketogenic insufficiency reprograms hepatic glycogen metabolism and the lipidome.
d'Avignon DA; Puchalska P; Ercal B; Chang Y; Martin SE; Graham MJ; Patti GJ; Han X; Crawford PA
JCI Insight; 2018 Jun; 3(12):. PubMed ID: 29925686
[TBL] [Abstract][Full Text] [Related]
20. FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort.
De A; Keisham A; Mishra S; Mehta M; Verma N; Premkumar M; Taneja S; Das A; Singh V; Duseja A
J Clin Exp Hepatol; 2022; 12(2):440-447. PubMed ID: 35535068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
